Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (121-130 of 218) with videos related to

Pageof 22
Sort By:
The British Journal of Dermatology|July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trialJürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
The Oncologist|March 31, 2026
MyCODE: A prospective evaluation of Lay-language Molecular Tumor Board Protocols in Precision OncologyIna Pretzell, Anke Fleischhauer, Ilektra Mavroeidi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2021
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyAnne Zaremba, Georg Lodde, Rajmohan Murali, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
Oncotarget|October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter studyJulia K Tietze, Andrea Forschner, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal of Translational Medicine|October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabDomenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeEleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
Pageof 22

Showing results (121-130 of 218) with videos related to

Sort By:
Pageof 22
The British Journal of Dermatology|July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trialJürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
The Oncologist|March 31, 2026
MyCODE: A prospective evaluation of Lay-language Molecular Tumor Board Protocols in Precision OncologyIna Pretzell, Anke Fleischhauer, Ilektra Mavroeidi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2021
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyAnne Zaremba, Georg Lodde, Rajmohan Murali, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
Oncotarget|October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter studyJulia K Tietze, Andrea Forschner, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal of Translational Medicine|October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabDomenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeEleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
Pageof 22